<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-18T23:16:33Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12007" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12007</identifier><datestamp>2026-10-18T21:13:17Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>The best anti-HCV S/Co values for reflecting HCV infection in a university hospital in the eastern part of Turkey</dc:title><dc:creator>Dabanlioǧlu, Bülent</dc:creator><dc:creator>Yilmaz, Aysun</dc:creator><dc:creator>Akyüz, Sümeyye</dc:creator><dc:creator>Gülhan, Bariş</dc:creator><dc:subject>anti-HCV</dc:subject><dc:subject>HCV RNA</dc:subject><dc:subject>S/Co</dc:subject><dc:subject>Hepacivirus</dc:subject><dc:subject>Hepatitis C</dc:subject><dc:subject>Hepatitis C Antibodies</dc:subject><dc:subject>Hospitals</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Retrospective Studies</dc:subject><dc:subject>RNA, Viral</dc:subject><dc:subject>Sensitivity and Specificity</dc:subject><dc:subject>Turkey</dc:subject><dc:subject>adult</dc:subject><dc:subject>aged</dc:subject><dc:subject>Article</dc:subject><dc:subject>chemiluminescent microparticle immunoassay</dc:subject><dc:subject>false positive result</dc:subject><dc:subject>female</dc:subject><dc:subject>Hepatitis C virus</dc:subject><dc:subject>human</dc:subject><dc:subject>major clinical study</dc:subject><dc:subject>male</dc:subject><dc:subject>predictive value</dc:subject><dc:subject>real time polymerase chain reaction</dc:subject><dc:subject>receiver operating characteristic</dc:subject><dc:subject>retrospective study</dc:subject><dc:subject>university hospital</dc:subject><dc:subject>viremia</dc:subject><dc:subject>architect</dc:subject><dc:subject>diagnosis</dc:subject><dc:description>Introduction: The measurement of hepatitis C virus (HCV) RNA is a test that requires high cost, advanced technique, and qualified personnel. Diagnosis and treatment of patients may be delayed due to the high rate of false-positive results. This study aims to predict true antibody positivity and viremia by determining the most appropriate anti-HCV signal-to-cutoff (S/Co) value reflecting HCV infection. Methodology: The presence of anti-HCV antibodies and HCV RNA levels were examined in 72341 people who applied to the Mengücek Gazi Training and Research Hospital between January 2018 and December 2020. The anti-HCV levels were determined by using the Abbot Architect i2000 SR device (Abbot Diagnostics, Chicago, IL, USA). The levels of HCV RNA were determined in the COBAS AmpliPrep/COBAS, TaqMan 48 (Roche, Diagnostics, Pleasanton, USA) devices using serum samples from patients. Our study is a retrospective and methodological study. Results: Of the 150 patients with anti-HCV antibodies, 50 (33.3%) were HCV RNA positive, and 100 (66.7%) were HCV RNA negative. Anti-HCV levels of HCV RNA-positive patients were statistically higher than HCV RNA-negative patients. The most appropriate anti-HCV S/Co value for diagnosing hepatitis C patients was 15.4. The sensitivity of this value was 72%, specificity 88%, positive predictive value (PPV) 73.5%, and negative predictive value (NPV) 86.1%. Receiver operating characteristic (ROC) curve was significantly higher than 0.5 (95% confidence interval 0.938-0.827). Conclusions: Correct approaches can be applied in the diagnosis of HCV infection using the anti-HCV S/Co value found in our study.  © 2024 Dabanlioǧlu et al.</dc:description><dc:publisher>Journal of Infection in Developing Countries</dc:publisher><dc:date>2024</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/12007</dc:identifier><dc:identifier>https://doi.org/10.3855/jidc.18105</dc:identifier><dc:identifier>2036-6590</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Infection in Developing Countries</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12007</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>